FR EA

Extract to table

Pull the structured facts out of a document: parties, dates, amounts, obligations.

Extract to table / ncd-feasibility-assessment-memo.docx
ncd-feasibility-assessment-memo.docx · 1013-00004

Parties

HARKNESS LLP
Genome Dx Therapeutics Inc

Dates

May 10, 2024
April 22, 2024
March 29, 2024
April 15, 2024
April 9, 2024
December 14, 2022
April 5, 2024
April 30, 2024
June 28, 2024
August 15, 2021

Amounts

$52,514,000
$28,500,000
$19,100,000
$9,400,000
$3,850
$20,290,500
$4,400
$34,502,500
$1.5
$3.0

Obligations

" This statutory "reasonable and necessary" standard is the fundamental evidentiary threshold that any NCD request must satisfy
MEDCAC preparation, if required, would involve significant advance work, including the identification and preparation of expert witnesses, development of presentation materials, and rehearsal of testimony, all of which must be factored into NCD resource planning
External requests are submitted to the CAG using CMS's standard NCD request form and must include a description of the technology, the proposed coverage criteria, and the supporting clinical evidence
Under Section 1869(f)(1)(B) of the Social Security Act, CMS is required to issue the final NCD within 12 months of accepting the formal NCD request
CAD does not require enrollment in a formal clinical study but does impose clinical eligibility and appropriateness requirements that must be documented by the ordering physician
The technology sponsor (in this case, GDT) must propose a CMS-approved study protocol that addresses the specific evidentiary questions identified by CMS